Venus Remedies Ltd. Hits Upper Circuit on BSE, 16 October 2026

On 16 October 2026, Venus Remedies Ltd. (VENUSREM) hit the upper circuit on BSE at Rs 1642.4, a 5% positive move from the previous close of Rs 1564.2. The company’s market cap stood at Rs 2090.86 crore. The upper circuit price for the session was Rs 1642.4.

The Venus Remedies upper circuit came as buying interest met the exchange-defined price band. At the time of writing the stock was locked at its upper circuit level, which makes the session worth noting for short-term market participants.

Key Takeaways

• Venus Remedies Ltd. (VENUSREM) hit the upper circuit on BSE at Rs 1642.4 on 16 October 2026.
• The session move was +5% against a previous close of Rs 1564.2.
• Market capitalisation stood at Rs 2090.86 crore with a PE ratio of 18.
• The most recent reported development, dated 16 October 2026 at 2:57 pm, is covered below.
• A price band is an exchange trading rule, not a view on the company or a recommendation.

Key Market Data

All figures above are as of 16 October 2026, sourced from Univest market data for the BSE listing. Only fields present in the source for this session are shown.

Price Action and Trading Activity

Venus Remedies Ltd. opened at Rs 1580.8 on BSE, compared with a previous close of Rs 1564.2. During the session, the stock traded between Rs 1570 and Rs 1642.4 before touching the upper circuit price of Rs 1642.4.

The absolute day change was Rs 78.2, while the percentage move was 5%. The event figures are kept to a single exchange so the numbers stay comparable.

The selected exchange matters because price bands, day range and previous-close values can differ across exchanges. This article uses BSE consistently for the event table and narrative. The stated upper circuit limit for the session was Rs 1642.4, which is the level the price reached.

Why Venus Remedies Ltd. Hit Upper Circuit

The most recent development reported for Venus Remedies Ltd., dated 16 October 2026 at 2:57 pm, is this: Venus Remedies Ltd has obtained five marketing approvals in Kazakhstan, Peru, Kuwait, and Argentina for key drugs including Vancomycin, Fluorouracil, Fulvestrant, Methotrexate, and Meropenem. This expansion significantly enhances the company’s global reach and strengthens its pharmaceutical product portfolio, potentially driving future revenue growth and market penetration.

That is the nearest dated development on record ahead of the upper circuit session. Whether it caused the move is not something the price data alone can confirm, so it is reported here as context rather than as an established cause.

Within the session the stock reached the upper circuit level of Rs 1642.4.

What the Venus Remedies Upper Circuit Means

An upper circuit is the maximum price level a stock is allowed to reach during a trading session under the applicable exchange price band. For Venus Remedies Ltd., the captured upper circuit price was Rs 1642.4 on 16 October 2026.

The circuit mechanism is meant to slow extreme price movement and keep trading orderly. It is a market-structure fact, not a return forecast. In this article, the upper circuit explains what happened in the session and where the price band was reached.

Venus Remedies Ltd. Fundamentals and Valuation

Available market data gives a fuller picture than price action alone. For Venus Remedies Ltd., PE ratio was 18, PB ratio was 3.04, book value was Rs 513.74, EPS was 86.91, ROE was 16.79%, ROCE was 21.88%, dividend yield was 0.64% and debt-to-assets ratio was 0, on a market cap of Rs 2090.86 crore. These are available financial indicators and should not be read as a buy, sell, or hold view.

At the reported PB ratio of 3.04, the market valued Venus Remedies Ltd. above its reported book value per share. That premium can reflect growth expectations, asset quality, or simply thin trading in a smaller counter.

For investors tracking upper circuit moves, these metrics help separate the price event from the broader financial profile. A sharp one-day move can attract attention, but valuation and return ratios still need to be reviewed separately.

Peer and Sector Context

Venus Remedies Ltd. belongs to the Pharmaceuticals & Drugs industry within the Healthcare sector. The peer table below uses available companies from the same sector or industry to give broader valuation context.

A dash in the PE column means no PE ratio was carried for that company in the source data, which happens when reported earnings are negative or have not been refreshed. Those companies are left out of the average below rather than counted as zero.

Venus Remedies Ltd.’s PE ratio was 18, compared with an available peer PE average of 73.69, calculated from the 3 peer companies that had a PE on record. This comparison is a valuation reference point, not a recommendation.

Technical Snapshot

The technical snapshot adds context: RSI was 49.97, the 50-day moving average was 1640.66 and the 200-day moving average was 1437.42.

What Readers Should Know

The main confirmed fact is that Venus Remedies Ltd. hit the upper circuit on BSE at Rs 1642.4 on 16 October 2026, with a 5% day move.

The practical limitation after an upper-circuit session is execution. Buyers queue at the band and sellers step back, so the quoted price is not necessarily a price you can transact at.

Readers should treat upper circuit events as market updates, not standalone investment conclusions. The price band shows strong near-term interest, but follow-up analysis should consider business fundamentals, valuation, liquidity, risk, and confirmed company disclosures.

Frequently Asked Questions

Why did Venus Remedies Ltd. hit upper circuit on 16 October 2026?

The stock reached its upper price band after buying interest during the session. The nearest dated development on record, from 16 October 2026 at 2:57 pm, is: Venus Remedies Ltd has obtained five marketing approvals in Kazakhstan, Peru, Kuwait, and Argentina for key drugs including Vancomycin, Fluorouracil, Fulvestrant, Methotrexate, and Meropenem. This expansion significantly enhances the company’s global reach and strengthens its pharmaceutical product portfolio, potentially driving future revenue growth and market penetration.

What was VENUSREM share price on 16 October 2026?

The last traded price used in this article was Rs 1642.4 on BSE. That price matched the upper circuit price captured for the event.

What was the upper circuit price for VENUSREM?

The upper circuit price was Rs 1642.4. The stated exchange upper circuit limit was Rs 1642.4. The event numbers in this article are aligned to BSE.

What is Venus Remedies Ltd.’s market cap and PE ratio?

Venus Remedies Ltd.’s market cap was Rs 2090.86 crore. PE ratio was 18.

Which exchange and data source were used?

The selected exchange was BSE. The article uses Univest market data available at the time of generation, captured on 16 October 2026.

Does hitting an upper circuit mean Venus Remedies Ltd. is a buy or a sell?

No. A circuit is an exchange price-band rule that caps how far a stock can move in a single session. It carries no view on valuation or business quality and is not a recommendation. Any decision should rest on fundamentals, valuation, liquidity and your own risk tolerance.

Can you buy or sell Venus Remedies Ltd. shares when the stock is at the upper circuit?

It is usually difficult. At the upper circuit, buy orders queue up while sellers step back, so there may be no counterparty at the quoted price. Orders can stay unfilled until the band opens up or sellers return.

What happens the next trading session after an upper circuit?

There is no fixed outcome. The band resets each session, so the stock can open freely, hit the same band again, or reverse. The exchange can also revise the applicable band width. The useful signals to watch are whether the company files any disclosure explaining the move.

What is the upper circuit limit set at for Indian stocks?

Exchange price bands are commonly set at 2%, 5%, 10% or 20% depending on the security, and the applicable band can be revised by the exchange. For Venus Remedies Ltd. the stated limit was Rs 1642.4. For this session, Venus Remedies Ltd. moved 5%.